NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1052 coverThe Future of Hormone Therapy: What Basic Science and Clinical Studies Teach Us Volume 1052 published June 2005
Ann. N.Y. Acad. Sci. 1052: 27–40 (2005). doi: 10.1196/annals.1347.003
Copyright © 2005 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via HighWire
Citing Articles via Google Scholar
Google Scholar
Articles by SCHMIDT, P. J.
Search for Related Content
PubMed
PubMed Citation
Articles by SCHMIDT, P. J.
Depression, the Perimenopause, and Estrogen Therapy

PETER J. SCHMIDT

Behavioral Endocrinology Branch, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA

Address correspondence to: Peter J. Schmidt, Behavioral Endocrinology Branch, National Institute of Mental Health, National Institutes of Health, Bldg. 10-CRC, Rm. 6-5340, 10 Center Dr., MSC 1276, Bethesda, MD 20892-1276. Voice: 301-496-6120; fax: 301-402-2588. peterschmidt{at}mail.nih.gov

The focus of this chapter is the relationship between the onset of depression in women and the reproductive events of the perimenopause. The perimenopause is a time of considerable variability in reproductive function, which appears in some women to be associated with an increased susceptibility to depression. Elevated gonadotropin levels occur during the late perimenopause, with plasma follicle-stimulating hormone levels increasing in association with impaired ovarian function and decreased estradiol secretion. It is unclear, however, whether the variability in ovarian hormone secretion during the perimenopause has a substantial causal role in the development of depression. Epidemiologic studies have documented that most women do not become depressed during the menopausal transition. However, recent longitudinal studies suggest that in some women, perimenopause-related reproductive events play a role in the onset of depression. Additionally, randomized controlled trials have documented the short-term (3-6 weeks) antidepressant efficacy of estradiol in depressed perimenopausal women. Thus, although depression is not a uniform accompaniment of the menopausal transition, in some women age-related changes in ovarian estrogen production may alter central nervous system function and predispose them to develop depression.

Key Words: perimenopause • depression • estrogen




This article has been cited by other articles:


Home page
J Law Med EthicsHome page
J. Schulkin
Hormone Therapy, Dilemmas, Medical Decisions.
J. Law Med. Ethics, March 1, 2008; 36(1): 73 - 88.
[PDF]



footerLeft footerRight